Company Filing History:
Years Active: 2008-2010
Title: Abdolsamad Tadayon: Innovator in Pharmaceutical Crystal Forms
Introduction
Abdolsamad Tadayon is an accomplished inventor based in Kirkland, California, known for his significant contributions to the pharmaceutical field. With a total of two patents, his work primarily focuses on novel crystal forms beneficial for therapeutic applications, particularly in the modulation of estrogenic receptors.
Latest Patents
Tadayon's latest patents showcase his innovative approach to drug formulation. The first patent is for the crystal forms of 2-(3-fluoro-4-hydroxyphenyl)-7-vinyl-1,3-benzoxazol-5-ol. This invention provides monohydrate and anhydrate forms of the compound, which is identified as an estrogenic receptor modulator useful in treating diseases related to abnormal estrogen levels. His second patent concerns crystalline polymorphs of (3S)-N-hydroxy-4-({4-[-(4-hydroxy-2-butynyl)oxy]phenyl}sulfonyl)-2,2-dimethyl-3-thiomorpholine carboxamide. This invention details the crystalline forms of the compound and discusses their preparation and potential therapeutic uses.
Career Highlights
Abdolsamad Tadayon has built an impressive career in pharmaceutical research and development at Wyeth, a well-known name in the industry. His expertise in creating stable and effective drug formulations has positioned him as a pivotal figure in advancing pharmaceutical sciences.
Collaborations
Throughout his career, Tadayon has worked alongside talented colleagues such as Silvio Iera and Hong Wen. These collaborations have enabled him to enhance his research efforts and broaden the scope of his inventions, leading to impactful advancements in drug development.
Conclusion
In summary, Abdolsamad Tadayon stands out as an innovative inventor in the field of pharmaceuticals. His two patents reflect a commitment to addressing critical health challenges through the development of novel drug formulations. His work not only exemplifies the spirit of innovation but also contributes significantly to the scientific community.